Pre-made Axatilimab biosimilar ( Whole mAb, anti-CSF1R therapeutic antibody, Anti-FMS/CSFR/FIM2/HDLS/C-FMS/CD115/HDLS1/CSF-1R/BANDDOS/M-CSF-R Antibody) for drug discovery and mechanism of action (MOA) research

Pre-Made Axatilimab biosimilar, Whole mAb, Anti-CSF1R Antibody: Anti-FMS/CSFR/FIM2/HDLS/C-FMS/CD115/HDLS1/CSF-1R/BANDDOS/M-CSF-R therapeutic antibody is a biosimilar expressed by mammalian cell line as a benchmark reference therapeutic antibody for biological drug disovery items including cell culture, assay development, animal model development, PK/PD model development (Pharmacokinetics & Pharmacodynamic) and mechanism of action (MOA) research.

Axatilimab (SNDX-6352) is a high-affinity antibody targeting the colony stimulating factor 1 receptor (CSF-1R). ... Axatilimab (SNDX-6352) is a high-affinity antibody targeting the colony stimulating factor 1 receptor (CSF-1R).

Order information

* GeneMedi provides NON-PROFIT PRICE to support Academic research. Please click inquiry for product quotation. → Inquiry

Catalog No.	Package	List Price(In USD)	Discount off	Discount Price
GMP-Bios-ab-042-1mg	1mg	3090	Inquiry	Inquiry

Size： 1mg | 10mg | 100mg

Description

Products Name (INN Index)	Pre-Made Axatilimab biosimilar, Whole mAb, Anti-CSF1R Antibody: Anti-FMS/CSFR/FIM2/HDLS/C-FMS/CD115/HDLS1/CSF-1R/BANDDOS/M-CSF-R therapeutic antibody
INN Name	Axatilimab
Target	CSF1R
Format	Whole mAb
Derivation
Species Reactivity	Human
CH1 Isotype	IgG4
VD LC	Kappa
Highest_Clin_Trial (Jan '20)	Phase-II
Est. Status	Active
100% SI Structure	None
99% SI Structure	None
95-98% SI Structure	None
Year Proposed	2019
Year Recommended	2020
Companies	Syndax Pharmaceuticals;AstraZeneca;UCB
Conditions Approved	na
Conditions Active	Cholangiocarcinoma;Graft-versus-host disease;COVID-19
Conditions Discontinued	Solid tumours
Development Tech	na